Exercise + Creatine After Colorectal Cancer: What This Pilot Trial Really Tells Us
Summary
If you or someone you love has been through colorectal cancer treatment, you already know chemotherapy doesn't just fight cancer—it can quietly erode muscle. Studies show losing muscle during colorectal cancer treatment is linked to a two- to four-fold higher mortality risk, yet more than half of survivors never regain their pre-treatment activity levels within six months. This new pilot trial, published in PLOS One, asked a deceptively simple question: can a structured resistance training program, boosted by creatine monohydrate (the same supplement gym-goers have used for decades), safely help this population rebuild strength—and is running a bigger trial to prove it even feasible?
Researchers at the University of South Carolina and Prisma Health randomized 27 colorectal cancer survivors (average age 64, all previously treated with chemotherapy, most with stage III or IV disease) into two groups. Both did the identical 10-week resistance training program: three supervised sessions per week (two in-person at a clinic, one live via Zoom), covering compound lifts like squats, chest presses, and rows. One group also took 5 g/day of creatine monohydrate (after a one-week loading phase of 20 g/day); the other took a matched placebo. Neither participants nor researchers knew who got what.
The headline result isn't really about creatine—it's about whether this kind of program can work at all in cancer survivors. And on that front, the news is good: 89% of participants stuck with the program to the end, attendance and supplement adherence both topped 90%, and participants rated the experience 4.6 out of 5 for satisfaction. No serious side effects were tied to the exercise or the supplement—just some mild, short-lived stomach upset in a few creatine users during the loading week, which resolved once they dropped to the maintenance dose.
Where the study fell short was recruitment: researchers aimed to enroll 40 people over two years but got only 27, after screening 410 candidates from cancer registries (just 6.6% converted to enrollment—well below the ~31% average seen in similar exercise-oncology trials).
As for creatine's added benefit—the honest answer is "unclear, not zero." Both groups gained modest strength and physical-function improvements from the exercise program itself, but creatine didn't produce statistically significant extra gains in grip strength, chest press, leg strength, lean mass, or body fat compared to placebo. There was a hint of a benefit in physical performance scores (SPPB) that didn't reach significance, and with only 13-14 people per group, the trial was simply too small and too short (10 weeks) to reliably detect real differences—especially since muscle-building effects of creatine typically take longer to show up.
What This Means For You
This was a feasibility study, not a definitive efficacy trial—so treat it as a green light for trying supervised resistance training after cancer treatment, not proof that creatine specifically will boost your results.
For exercise: The biggest actionable takeaway is that structured resistance training—three sessions a week, mixing in-person and virtual supervision—is safe, well-tolerated, and produced modest strength and functional gains in people who'd been through chemotherapy, regardless of supplement group. If you're a cancer survivor, this supports current exercise-oncology guidelines (from ACSM and ASCO) recommending resistance training 2+ times/week. Seek out programs with individualized supervision, especially early on—participants specifically credited 1:1 coaching with reducing fear of injury and keeping them engaged.
For creatine: The dosing used here—5 g/day maintenance after a 7-day, 20 g/day loading phase—mirrors standard consumer-label directions and matches doses used in dozens of trials in older adults with a strong safety record (no adverse kidney or liver effects reported across the broader literature). If you already take creatine for general fitness, this trial gives no reason to stop, but also no strong evidence it will meaningfully accelerate strength or muscle recovery specifically after cancer treatment within 10 weeks. If gut discomfort occurs during loading, this study confirms the common fix: skip loading and go straight to 5 g/day, or reduce the dose—symptoms resolved quickly.
Who might benefit most: Motivated survivors with reasonably good baseline physical function (this sample averaged 10-11/12 on a mobility test, higher than many patients). More frail, sarcopenic, or newly-treated patients weren't well represented, so caution is warranted in extrapolating.
Cost consideration: Creatine monohydrate is inexpensive (often $15-25/month at 5g/day), low-risk, and well-studied, making it a reasonable low-stakes addition alongside—not instead of—supervised exercise, but don't expect it alone to replace structured training.
Important Considerations
This was explicitly a pilot/feasibility trial, not designed or powered to prove creatine works—the researchers say so themselves, and any "no significant difference" findings should be read as "we couldn't tell" rather than "creatine doesn't help." With only 13-14 people per group, even meaningful real-world effects could easily be missed statistically.
The sample skews toward motivated, relatively high-functioning survivors (recruitment captured just 6.6% of those screened), so results may not generalize to more frail, sarcopenic, or recently-treated patients—arguably the people who'd benefit most from muscle-preserving interventions.
Ten weeks is short for detecting creatine's muscle-building effects, which typically build over months, not weeks. There was also no way in this study to separate creatine-related water retention in muscle (which happens quickly and can look like "gains" on a DXA scan) from true muscle tissue growth, since no separate body-water measurement was taken.
There was also no non-exercise control group—so while it's tempting to credit the exercise program for the modest strength gains seen in both arms, technically this trial can't rule out other explanations. And one nominally "significant" finding here (lower financial-difficulty scores in the creatine group) showed up amid more than 20 comparisons, which is a classic setup for a chance finding—the researchers themselves urge caution interpreting it.
Finally, this trial was partly funded in-kind by AlzChem, the creatine manufacturer, which supplied the creatine and placebo (though not the study's design or interpretation). As always, individuals with kidney disease, or those on medications affecting renal function, should consult their oncology or primary care team before starting creatine.
Terms Explained
Technical Study Details
Study Design
Total Score
JADAD Quality Assessment評価詳細
Randomization
2 / 2Blinding
2 / 2Dropouts/Withdrawals
1 / 1Study Population
- Adults previously treated for colorectal cancer
- Prior chemotherapy exposure (added as inclusion criterion during protocol amendment)
- Amended protocol removed original requirements of ≥12 months post-treatment and confirmed sarcopenia
Interventions
Creatine monohydrate (Creapure)
TreatmentCorn-starch maltodextrin placebo
ControlHybrid resistance exercise training (RET)
TreatmentOutcomes
| Outcome | Type | Effect | p-value |
|---|---|---|---|
| Recruitment rate | Primary | - | - |
| Retention rate | Primary | - | - |
| Adherence to RET (Relative Dose Intensity) | Primary | - | - |
| Adherence to supplementation | Primary | - | - |
| Intervention acceptability/satisfaction | Primary | - | - |
| Adverse events | Secondary | - | - |
| Handgrip strength | Secondary | 0.06 (-3.28-3.40) | p=0.97 |
| Chest press strength (1RM) | Secondary | 0.44 (-3.71-4.59) | p=0.83 |
| Leg extension strength (1RM) | Secondary | 2.04 (-5.45-9.58) | p=0.57 |
| Lean soft tissue (LST) | Secondary | 0.97 (-1.63-3.57) | p=0.45 |
| Appendicular lean mass (ALM) | Secondary | 0.48 (-0.60-1.55) | p=0.37 |
| Height-adjusted ALM index | Secondary | 0.23 (-0.14-0.59) | p=0.21 |
| Total fat mass | Secondary | 0.02 (-1.93-1.97) | p=0.98 |
| Visceral fat | Secondary | -0.04 (-0.14-0.06) | p=0.46 |
| Body fat percentage | Secondary | -0.46 (-2.54-1.63) | p=0.65 |
| Bone mineral density | Secondary | -0.02 (-0.04-0.00) | p=0.11 |
| Short Physical Performance Battery (SPPB) score | Secondary | - | p=0.08 |
| EORTC QLQ-C30 overall functioning | Secondary | -6.86 (-16.18-2.45) | p=0.14 |
| EORTC QLQ-C30 physical functioning | Secondary | -0.16 (-5.54-5.22) | p=0.95 |
| EORTC QLQ-C30 role functioning | Secondary | 2.13 (-4.20-8.47) | p=0.49 |
| EORTC QLQ-C30 emotional functioning | Secondary | -5.73 (-12.67-1.20) | p=0.1 |
| EORTC QLQ-C30 cognitive functioning | Secondary | 3.89 (-5.91-13.68) | p=0.42 |
| EORTC QLQ-C30 social functioning | Secondary | -10.70 (-25.60-4.20) | p=0.15 |
| EORTC QLQ-C30 Financial Difficulties subscale | Secondary | -13.52 (-26.24--0.80) | p=0.04Significant |
| SarQoL overall score | Secondary | -5.06 (-11.53-1.41) | p=0.12 |
Safety
Conclusion
A 10-week hybrid (in-clinic and virtual) resistance exercise training program, with or without creatine monohydrate supplementation, was feasible, acceptable, safe, and well tolerated in individuals previously treated for colorectal cancer with chemotherapy, once participants were enrolled (high retention [88.9%], strong RET and supplement adherence [>85%], high acceptability, and no serious intervention-related adverse events). However, recruitment via cancer registries was challenging, with only 6.6% of those assessed for eligibility enrolling, falling short of the target sample size of 40. Both groups showed modest within-group improvements in muscular strength and SPPB scores, but no statistically significant between-group differences were observed for any secondary outcome (body composition, strength, physical function, or quality of life), so creatine did not demonstrate clear additive effects over RET alone in this small pilot trial. Findings support advancing to a larger, adequately powered, longer-duration efficacy trial with an improved recruitment strategy and a non-exercise comparator.Limitations
- Small sample size (n=27) and narrow sample characteristics limit generalizability
- Low recruitment rate (6.6%) and relatively high baseline physical function (SPPB ~10-11 of 12) suggest possible selection/volunteer bias toward more motivated and physically capable participants
- Findings may not generalize to more vulnerable individuals, including those who are sarcopenic, frail, or more recently treated
- Creatine supplementation may increase total body water, potentially confounding DXA-derived lean soft tissue estimates; no bioelectrical impedance measure was used to distinguish fluid shifts from true tissue accretion
- 10-week intervention duration may be insufficient to detect hypertrophic adaptations, which typically emerge over longer training periods
- No multi-compartment (four-compartment) body composition model or total body water measurement (e.g., deuterium dilution) was used
- Home-based equipment (kettlebells, resistance bands) for remote sessions may constrain progressive loading relative to in-clinic machines
- Absence of a non-exercise control group means observed changes cannot be attributed to RET specifically
- Trial was not powered for between-group efficacy comparisons; null effects for creatine should be interpreted cautiously rather than as evidence of no benefit
- Several secondary outcomes (particularly quality-of-life measures) showed departures from ANCOVA model assumptions (non-normal residuals, heteroscedasticity, influential observations), though sensitivity analyses using HC3 standard errors did not materially alter conclusions